LAMP2
Lysosome-associated membrane glycoprotein 2
Also known as: CD107b, LAMP2_HUMAN
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- P13473
- Gene
- LAMP2
- Ensembl
- ENSG00000005893
- Chromosome
- X
- Canonical length
- 410 aa
- Protein class
- CD markers, Disease related genes, Human disease related genes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Transporters
- Subcellular location
- Vesicles
- Quaternary structure
- Homotrimer
OverviewNCBI Gene
The protein encoded by this gene is a member of a family of membrane glycoproteins. This glycoprotein provides selectins with carbohydrate ligands. It may play a role in tumor cell metastasis. It may also function in the protection, maintenance, and adhesion of the lysosome. Alternative splicing of this gene results in multiple transcript variants encoding distinct proteins. [provided by RefSeq, Jul 2008]
Canonical amino-acid sequenceUniProt
410 residues, UniProt reviewed canonical sequence.
>P13473|LAMP2
1 MVCFRLFPVP GSGLVLVCLV LGAVRSYALE LNLTDSENAT CLYAKWQMNF TVRYETTNKT
61 YKTVTISDHG TVTYNGSICG DDQNGPKIAV QFGPGFSWIA NFTKAASTYS IDSVSFSYNT
121 GDNTTFPDAE DKGILTVDEL LAIRIPLNDL FRCNSLSTLE KNDVVQHYWD VLVQAFVQNG
181 TVSTNEFLCD KDKTSTVAPT IHTTVPSPTT TPTPKEKPEA GTYSVNNGND TCLLATMGLQ
241 LNITQDKVAS VININPNTTH STGSCRSHTA LLRLNSSTIK YLDFVFAVKN ENRFYLKEVN
301 ISMYLVNGSV FSIANNNLSY WDAPLGSSYM CNKEQTVSVS GAFQINTFDL RVQPFNVTQG
361 KYSTAQDCSA DDDNFLVPIA VGAALAGVLI LVLLAYFIGL KHHHAGYEQFLocalizationUniProt · AlphaFold · HPA
Whether an antibody against LAMP2 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Cell surface
- Secreted
- No
- Transmembrane segments
- 1
- Mean surface accessibility (rSASA)
- 0.35
- Highest tissue expression
- 142 nTPM
Expression across tissuesHPA
Tissue
- spinal cord: 142 nTPM
- liver: 128 nTPM
- skeletal muscle: 107 nTPM
- cerebral cortex: 92 nTPM
- midbrain: 89 nTPM
- hippocampal formation: 85 nTPM
Single-cell type
- neutrophils: 800 nCPM
- esophageal apical cells: 611 nCPM
- oligodendrocytes: 577 nCPM
- syncytiotrophoblasts: 573 nCPM
- neutrophil progenitors: 365 nCPM
- esophageal suprabasal cells: 319 nCPM
Immune cell
- neutrophil: 564 nTPM
- eosinophil: 226 nTPM
- classical monocyte: 116 nTPM
- intermediate monocyte: 98 nTPM
- non-classical monocyte: 98 nTPM
- total PBMC: 67 nTPM
Brain region
- white matter: 437 nTPM
- basal ganglia: 293 nTPM
- medulla oblongata: 246 nTPM
- midbrain: 228 nTPM
- cerebellum: 219 nTPM
- thalamus: 204 nTPM
DiseaseUniProt · ClinVar · IEDB · PubMed
Four sources answering four different questions about LAMP2.
Disease | AllUniProt
Conditions LAMP2 is implicated in, by any mechanism.
- Danon disease (DAND) MIM:300257
Disease | GeneticClinVar
148 pathogenic / likely-pathogenic of 936 ClinVar records.
Conditions with pathogenic or likely-pathogenic variants.
- Danon disease
- Cardiovascular phenotype
- Hypertrophic cardiomyopathy
- Primary dilated cardiomyopathy
- Thyroid cancer, nonmedullary, 1
Disease | AutoantibodyPubMed
Conditions in which antibodies against LAMP2 are reported. Each links to that disease's full target list.
ReferencesPubMed · IEDB
Publications for LAMP2 from three distinct lines of evidence, kept separate because they answer different questions: whether antibodies are directed at the protein, whether a B-cell epitope has been mapped on it, and whether a T-cell epitope has. Each is labelled with its source.
Reference: AutoantibodyPubMed
16 publications
- Molecular mimicry in pauci-immune focal necrotizing glomerulonephritis.
2008 · Nat Med · RCR 7.4 · 312 citations - High prevalence of autoantibodies to hLAMP-2 in anti-neutrophil cytoplasmic antibody-associated vasculitis.
2012 · J Am Soc Nephrol · RCR 3.3 · 100 citations - Neutrophil extracellular trap formation is associated with autophagy-related signalling in ANCA-associated vasculitis.
2015 · Clin Exp Immunol · RCR 3.2 · 93 citations - Anti-LAMP-2 antibodies are not prevalent in patients with antineutrophil cytoplasmic autoantibody glomerulonephritis.
2012 · J Am Soc Nephrol · RCR 3 · 93 citations - Autoantibodies to hLAMP-2 in ANCA-negative pauci-immune focal necrotizing GN.
2014 · J Am Soc Nephrol · RCR 1.5 · 46 citations
Show 11 more
- The contribution of genetic variation and infection to the pathogenesis of ANCA-associated systemic vasculitis.
2010 · Arthritis Res Ther · RCR 1.4 · 49 citations - New advances in the pathogenesis of ANCA-associated vasculitides.
2009 · Clin Exp Rheumatol · RCR 1.2 · 40 citations - What is the evidence for antibodies to LAMP-2 in the pathogenesis of ANCA associated small vessel vasculitis?
2013 · Curr Opin Rheumatol · RCR 0.7 · 21 citations - Lysosomal-associated membrane protein-2 plays an important role in the pathogenesis of primary cutaneous vasculitis.
2013 · Rheumatology (Oxford) · RCR 0.6 · 16 citations - Elevated antilysosomal-associated membrane protein-2 antibody levels in patients with adult Henoch-Schönlein purpura.
2012 · Br J Dermatol · RCR 0.4 · 13 citations - Anti-LAMP-2 autoantibodies in ANCA-associated pauci-immune glomerulonephritis.
2012 · J Am Soc Nephrol · RCR 0.4 · 12 citations - Autoantibodies Against Lysosome Associated Membrane Protein-2 (LAMP-2) in Pediatric Chronic Primary Systemic Vasculitis.
2020 · Front Immunol · RCR 0.4 · 6 citations - Serum anti-lysosomal-associated membrane protein-2 antibody levels in cutaneous polyarteritis nodosa.
2013 · Acta Derm Venereol · RCR 0.4 · 10 citations - Typical cutaneous small-vessel vasculitis induced by combined injection of antiphosphatidylserine/prothrombin complex antibody and anti-LAMP-2 antibody in normal rats.
2022 · J Dermatol · RCR 0.1 · 1 citations - Is There a Role for LAMP-2 Autoantibodies in Patients with Antineutrophil Cytoplasmic Antibody-associated Vasculitis?
2020 · J Rheumatol · RCR 0.1 · 1 citations - Anti-LAMP-2 Antibody Seropositivity in Children with Primary Systemic Vasculitis Affecting Medium- and Large-Sized Vessels.
2024 · Int J Mol Sci
Sources: PubMed — antigen-level antibody evidence from a custom retrieval. Records matching a controlled set of autoantibody terms (the MeSH descriptors Autoantibodies and Autoantigens, with title and abstract term variants) were obtained through NCBI E-utilities, and their titles and abstracts parsed for constructions that direct an antibody at a named protein rather than for co-occurrence. Captured names were resolved against UniProt nomenclature and each antigen adjudicated individually against the source text. Bibliographic records from PubMed and MeSH, U.S. National Library of Medicine; citation metrics from NIH iCite (Hutchins et al., PLoS Biology 2016). Titles link to PubMed; abstracts are not reproduced here. The NLM does not endorse this analysis.
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 0.64
- gnomAD pLI
- 0.27
- gnomAD missense Z
- 0.84
- DepMap mean gene effect
- 0.18
- DepMap dependency class
- none
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 5% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
- autophagosome maturation
- cellular response to starvation
- chaperone-mediated autophagy
- lysosomal lumen acidification
- lysosomal protein catabolic process
- muscle cell cellular homeostasis
- negative regulation of NLRP3 inflammasome complex assembly
- negative regulation of protein-containing complex assembly
- positive regulation of ferroptosis
- protein catabolic process
- protein import
- protein stabilization
- protein targeting
- protein targeting to lysosome involved in chaperone-mediated autophagy
- regulation of protein stability
Molecular functions
- enzyme binding
- ion channel inhibitor activity
- protein domain specific binding
- protein-macromolecule adaptor activity
- signaling adaptor activity
Cellular components
- autolysosome
- autophagosome membrane
- azurophil granule membrane
- extracellular exosome
- extracellular space
- ficolin-1-rich granule membrane
- late endosome
- late endosome membrane
- lysosomal lumen
- lysosomal membrane
- lysosome
- membrane
- perinuclear region of cytoplasm
- phagocytic vesicle membrane
- plasma membrane
- platelet dense granule membrane
- trans-Golgi network
- chaperone-mediated autophagy translocation complex
Protein domainsUniProt · Pfam · InterPro
- Lysosome-associated membrane glycoprotein
- Lysosome-associated membrane glycoprotein, conserved site
- Lysosome-associated membrane glycoprotein 2-like, transmembrane domain
- Lysosome-associated membrane glycoprotein 2-like, luminal domains
- Lysosome-associated membrane glycoprotein 2-like, luminal domains
- Lysosome-associated membrane glycoprotein 2, transmembrane segment
KeywordsUniProt
InteractionsUniProt · HPA
Protein binding partners of LAMP2 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads LAMP2 as an antibody target. Whether an autoantibody or antibody against LAMP2 could matter depends on whether native LAMP2 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
LAMP2 is annotated at the cell surface, where native LAMP2 is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.
Annotation status
The present source text does not explicitly label LAMP2 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...